1
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Marc J Ostro, Micrea C Popescu: Stable plurilamellar vesicles, their preparation and use. The Liposome Company, Pennie & Edmonds, June 11, 1985: US04522803 (204 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.


2
Andrew S Janoff, Pieter R Cullis, Marcel B Bally, Michael W Fountain, Richard S Ginsberg, Michael J Hope, Thomas D Madden, Hugh P Schieren, Regina L Jablonski: Dehydrated liposomes. The Liposome Company, Allen Bloom, Catherine L Kurtz, November 14, 1989: US04880635 (98 worldwide citation)

Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. F ...


3
Andrew S Janoff, Mircea C Popescu, Alan L Weiner, Lois E Bolcsak, Paul S Tremblay: Steroidal liposomes. The Liposome Company, Allen Bloom, Thomas M Saunders, January 26, 1988: US04721612 (92 worldwide citation)

Methods and compositions are described for the preparation of lipid vesicles, the bilayers of which comprise a salt form of an organic acid derivative of a sterol such as the tris-salt form of a sterol hemisuccinate. The method is rapid, efficient, and does not require the use of organic solvents. T ...


4
Pieter R Cullis, Marcel B Bally, Michael J Hope, Andrew S Janoff, Lawrence D Mayer: Multilamellar liposomes having improved trapping efficiencies. The Liposome Company, Allen Bloom, Catherine L Kurtz, December 4, 1990: US04975282 (81 worldwide citation)

A multilamellar vesicle dispersed in an aqueous phase comprising an aqueous medium, a lipid concentration of at least about 50 mg/ml and a trapping efficiency of at least about 40 percent. The vesicle can be prepared by dispersing the lipid in an aqueous phase to form a multilamellar vesicle, rapidl ...


5
Mircea C Popescu, Paul A Tremblay, Andrew S Janoff, Marc J Ostro, Elaine Chan, Alan Weiner: Pharmacological agent-lipid solution preparation. The Liposome Company, Allen Bloom, Ilene Janofsky, October 13, 1992: US05154930 (72 worldwide citation)

A pharmacological agent-lipid solution preparation comprising a lipophilic pharmacological agent, a desalted charged lipid and an aqueous-miscible lipid solvent such that upon introduction into an aqueous medium a suspension of lipid aggregates associated with the pharmacological agent are formed, a ...


6
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Ronald G Ort, December 8, 1992: US05169637 (71 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


7
Robert P Lenk, Michael W Fountain, Andrew S Janoff, Mircea C Popescu, Steven J Weiss, Richard S Ginsberg, Marc J Ostro, Sol M Gruner: Stable plurilamellar vesicles. The Liposome Company, Allen Bloom, Thomas M Saunders, Ronald G Ort, July 9, 1991: US05030453 (68 worldwide citation)

A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing ...


8
Andrew S Janoff, Mircea C Popescu, Carl R Alving, Michael W Fountain, Robert P Lenk, Marc J Ostro, Paul A Tremblay, Alan L Weiner: Drug preparations of reduced toxicity. The Liposome Company, Allen Bloom, Catherine L Kurtz, October 22, 1991: US05059591 (49 worldwide citation)

Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.


9
Mircea C Popescu, Alan L Weiner, Marie S Recine, Andrew S Janoff, Leonard Estis, Lynn D Keyes, Carl R Alving: Potentiation of immune responses with liposomal adjuvants. The Liposome Company, Kenneth B Rubin, Rosanne Goodman, July 18, 2000: US06090406 (40 worldwide citation)

A high integrity liposome comprising at least one stabile lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use. Immunizing dosage forms comprising a lipo ...


10
Andrew S Janoff, Mircea C Popescu, Alan L Weiner, Lois E Bolscak, Paul A Tremblay, Christine E Swenson: Steroidal liposomes. The Liposome Company, Allen Bloom, Thomas M Saunders, January 2, 1990: US04891208 (40 worldwide citation)

Steroidal liposomes comprising a bioactive agent and method for their administration are disclosed, the bilayers of said steroidal liposomes comprising a salt form of a carboxylic acid derivative of a sterol, a salt form of a polycarboxylic acid derivative of a sterol, a salt form of a hydroxy carbo ...